Generic drugs | Intellepedia

IPR and Access to Affordable Medicines: How affordable are We?

This post examines the complex interaction between intellectual property rights and access to affordable medicines in India. It provides a legal analysis of policy challenges and judicial decisions, highlighting the ongoing balance between innovation and public access to healthcare.

Extension of Waiver for Pharma Patents until 2033 A.D.

The WTO has extended the waiver on pharmaceutical patent enforcement for least developed countries until 2033. This move ensures continued access to affordable generics from India and highlights the ongoing tension between patient access and patent rights.

Merck v. Glenmark – A Bitter Battle of Pills

The Delhi High Court restrained Glenmark from manufacturing and marketing generic versions of Merck’s patented antidiabetic drugs. This case underscores key principles of Indian patent law and the balance between patent rights and public interest.

Gilead, IPA, Natco & The Bells of Harmony

The post examines the collaboration between Gilead, IPA, and Natco Pharma regarding the sofosbuvir patent in India. It analyses how voluntary licensing and innovative policies are improving access to affordable medicines while balancing public health and patent rights.

Patent Infringement Claim on Cancer Treatment Drug

The UK Court of Appeal ruled that Actavis’s alternative salt forms of pemetrexed would indirectly infringe Eli Lilly’s cancer drug patent. The decision provides insights into patent claim construction and the approach to pharmaceutical patent disputes across multiple European jurisdictions.

Mylan settles Patent Litigation with Pfizer

Mylan has reached a settlement with Pfizer over patent litigation related to Sildenafil, allowing earlier generic market entry in the US. This agreement is expected to lower drug prices and may signal a trend for further settlements involving Indian pharmaceutical companies.

‘Killead’s Patent Application Killed by the Indian Patent Office!

Gilead’s patent for Sofosbuvir was rejected by the Indian Patent Office on grounds of insufficient therapeutic efficacy. This landmark decision enables wider access to affordable generic Hepatitis C treatments in India.